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❚ Evidence summary
Patients with severe acute alcoholic 
hepatitis have elevated levels of serum 
tumor necrosis factor (TNF), suggesting 
that TNF release may play a role in liver 
infl ammation.1 Because pentoxifylline 
inhibits TNF synthesis, it has been evalu-
ated as a potential therapy for alcoholic 
hepatitis.
Decreases in mortality and 
hepatorenal syndrome
In a hospital-based clinical trial, 101 
patients admitted with severe alcoholic 
hepatitis (mean age 42 years, 74% men) 
were randomized to oral pentoxifylline 
400 mg twice a day or placebo (vita-
min B12 tablets) for 4 weeks.
1 The main 
outcome measures were short-term sur-
vival and progression to hepatorenal 
syndrome. Severe alcoholic hepatitis was 
defi ned as a Maddrey discriminant fac-
tor (DF) >32, jaundice, and at least one 
of the following: tender hepatomegaly, 
fever, leukocytosis, hepatic encephalopa-
thy, or hepatic systolic bruit. The DF is 
calculated as follows: 4.6 × [prothrombin 
time in seconds – control time] + biliru-
bin (mg/dL). Medical management was 
“individualized according to each pa-
tient’s condition.” 
Pentoxifylline therapy was associ-
ated with decreased mortality during 
the index hospitalization (relative risk 
[RR]=0.59; 95% confi dence interval 
[CI], 0.35-0.97; number needed to treat 
[NNT]=5). Hepatorenal syndrome also 
decreased (RR=0.29; 95% CI, 0.13-
0.65; NNT=4). Patients in the pentoxi-
fylline group tended to have more head-
aches and gastrointestinal side effects, 
but no other serious health hazards were 
observed.
In a recently published abstract, 50 
patients with severe alcoholic hepatitis 
(defi ned as DF >32) were enrolled in 
a randomized, double-blind, placebo-
controlled trial of oral pentoxifylline, 
400 mg twice a day or placebo for 4 
weeks.2 Short-term survival and changes 
in laboratory values (TNF, creatinine, and 
DF) were the primary outcome measures. 
Survival was 76% in the pentoxifyl-
line group compared with 60% in the 
How does pentoxifylline 
affect survival of patients 
with alcoholic hepatitis?
Evidence-based answer
Pentoxifylline improves short-term 
survival in patients admitted to the 
hospital with severe alcoholic hepatitis 
(strength of recommendation [SOR]: B, a 
single published randomized controlled 
trial [RCT]). Pentoxifylline does not improve 
survival when it is substituted for steroids 
in hospitalized patients who aren’t 
responding to steroids (SOR: C, case 
series). 
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Survival was 
76% in the 
pentoxifylline 
group compared 
with 60% in the 
placebo group 
placebo group (P not given). In the sub-
group of patients who died, however, 
hepatorenal syndrome was the cause 
of death in 83% of the pentoxifylline 
group and 60% of the placebo group (P
not given).
In a 1991 pilot study, also published 
only in abstract form, 22 patients admit-
ted to the hospital with severe alcoholic 
hepatitis were randomized to receive 
oral pentoxifylline (1200 mg daily) or 
placebo for 10 days. Serum creatinine 
dropped 0.3 mg/dL in the treatment 
group and rose 2.1 mg/dL in the control 
group (P<.05). At 30 days, 3 patients in 
the control group had died compared 
with 1 in the treatment group (P=not 
signifi cant).3 
It’s not effective for patients 
who don’t respond to steroids
A cohort study evaluated the effect of 
switching to pentoxifylline in hospital-
ized patients with severe alcoholic hepa-
titis who didn’t respond to initial therapy 
with steroids. Researchers identifi ed 121 
patients who were treated initially with 
40 mg oral prednisolone daily. The 36 pa-
tients who failed to show a drop in biliru-
bin levels within 7 days were switched to 
oral pentoxifylline, 400 mg twice a day. 
In the pentoxifylline group, 69% of 
patients died within 2 months, 27.6% 
of whom had some form of renal insuf-
fi ciency. This outcome wasn’t statisti-
cally different from that of 58 matched 
historical controls with severe alcoholic 
hepatitis who were maintained on oral 
prednisolone despite failure to re-
spond within the fi rst week of thera-
py (65% mortality, 20% with renal 
insuffi ciency).4
Recommendations
The American College of Gastroenterol-
ogy doesn’t recommend giving pentoxi-
fylline to patients with severe alcoholic 
hepatitis, citing lack of evidence for im-
provement of patient-oriented outcomes.5
However, a group of French hepatolo-
gists consider pentoxifylline a reasonable 
alternative to corticosteroids for severe 
acute alcoholic hepatitis based on the 
studies cited here.6 ■
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